Author:
Jonat Walter,Hilpert Felix,Maass Nicolai
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference16 articles.
1. ATAC Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139
2. ATAC Trialists’ Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810
3. ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62
4. BIG 1-98 Collaborative Group (2005) BIG 1-98: a prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast 14:S3
5. Boccardo F, Rubagotti A, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Preliminary results of the Italian Tamoxifen Anastrozole (ITA) trial. J Clin Oncol 23:5138–5147
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献